Nuttavut Sumransub

10PUBLICATIONS
54CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Tumour immunologyTransplantation immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jun 24, 2026
Efficacy of post-transplant brentuximab vedotin maintenance by pre-transplant disease status in relapsed/refractory classic Hodgkin lymphoma.

|Dec 17, 2025
PD-1-based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma.

Sanjal H Desai, Alison J Moskowitz, Reid W Merryman

|Mar 27, 2025
Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers.

Timothy J Voorhees, Eric M McLaughlin, Pallawi Torka

|Aug 29, 2024
Patients with TP53-Mutated Acute Myeloid Leukemia Receiving Intensive Induction Therapy Have Superior Outcomes Due to a Higher Rate of Salvage Therapy: A Single Institution, Retrospective Study.

Nuttavut Sumransub, Gabriel K Steinwand, Keith Cordner

|Mar 09, 2024
Kikuchi-Fujimoto disease mimicking T-cell lymphoma after COVID-19 vaccination.

Nuttavut Sumransub, Veronika Bachanova, Michael A Linden

|Nov 17, 2023
Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy.

Madiha Iqbal, Deepa Jagadeesh, Julio Chavez

Pageof 2

Frequent Collaborators

5 joint publications

Sanjal H Desai

3 joint publications

Gaurav Goyal

3 joint publications

Veronika Bachanova

2 joint publications

Narendranath Epperla